Bristol-Myers Squibb Company
Therapeutic TREM-1 peptides

Last updated:

Abstract:

A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.

Status:
Grant
Type:

Utility

Filling date:

14 Dec 2015

Issue date:

31 Mar 2020